Directed functional brain connectivity is altered in sub-threshold amyloid-β accumulators
==========================================================================================

* Mite Mijalkov
* Dániel Veréb
* Anna Canal-Garcia
* Giovanni Volpe
* Joana B. Pereira
* Alzheimer’s Disease Neuroimaging Initiative

## Abstract

Several studies have shown that amyloid-β (Aβ) deposition below the clinically relevant cut-off levels is associated with subtle changes in cognitive function and increases the risk for developing future Alzheimer’s disease (AD). Although functional MRI is sensitive to early alterations occurring during AD, sub-threshold changes in Aβ levels have not been linked to functional connectivity measures. This study aimed to apply directed functional connectivity to identify early changes in network function in cognitively unimpaired participants who, at baseline, exhibit Aβ accumulation below the clinically relevant threshold. To this end, we analyzed baseline functional MRI data from 113 cognitively unimpaired participants of the Alzheimer’s Disease Neuroimaging Initiative cohort who underwent at least one 18F-florbetapir-PET after the baseline scan. Using the longitudinal PET data, we classified these participants as Aβ negative (Aβ−) non-accumulators (n=46) and Aβ-accumulators (n=31). We also included 36 individuals who were amyloid-positive (Aβ+) at baseline and continued to accumulate Aβ (Aβ+ accumulators). For each participant, we calculated whole-brain directed functional connectivity networks using our own anti-symmetric correlation method and evaluated their global and nodal properties using measures of network segregation (clustering coefficient) and integration (global efficiency). When compared to Aβ-non-accumulators, the Aβ-accumulators showed lower global clustering coefficient. Moreover, the Aβ+ accumulator group exhibited reduced global efficiency and clustering coefficient, which at the nodal level mainly affected the superior frontal gyrus, anterior cingulate cortex and caudate nucleus. In Aβ-accumulators, global measures were associated with lower baseline regional PET uptake values, as well as higher scores on the Modified Preclinical Alzheimer Cognitive Composite. Our findings indicate that directed connectivity network properties are sensitive to subtle changes occurring in individuals who have not yet reached the threshold for Aβ positivity, which makes them a potentially viable marker to detect negative downstream effects of very early Aβ pathology.

**Significance Statement**

*   Directed functional connectivity measures are sensitive to very early changes in amyloid-β deposition.

*   Amyloid-β burden is associated with decreases in global and nodal directed measures of network integration and segregation.

*   Measures of directed network integration and segregation are associated with subclinical cognitive changes in Aβ-negative accumulators.

Keywords
*   Functional MRI directed functional connectivity
*   anti-symmetric correlations
*   amyloid-β positron emission tomography
*   preclinical AD
*   longitudinal amyloid-β accumulation

## Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder that results in a progressive loss of memory and other cognitive functions1. However, the pathological processes in AD begin many years before any symptoms of dementia and other cognitive impairments become apparent2. In particular, Aβ accumulation, which can be measured by an increased burden in amyloid positron emission tomography (PET), is an early sign of preclinical AD stages, being one of the first events in the sequence of pathological processes that ultimately results in the development of dementia3,4.

Although Aβ plaques are a hallmark of AD, studies using amyloid PET imaging found they are also present in the brains of otherwise healthy older individuals who show no indications of cognitive impairment5, 6. The deposition of Aβ in such individuals occurs over a very long time period7 and results in changes in the functional connectivity patterns8. However, widespread Aβ changes may not be necessary for observing connectivity changes 9. Instead, such effects can be evident also in the presence of emergent Aβ pathology9, the process of amyloid accumulation in cognitively healthy people who have not yet reached the threshold for clinical Aβ positivity. Such emergent pathology has been associated with higher tau accumulation and atrophy rates, as well as memory impairment and alterations in functional connectivity in previous studies10–14.

Here, we assessed whether early Aβ accumulation in otherwise healthy, cognitively normal individuals that are Aβ-negative at baseline has an effect on the organization of whole-brain directed functional connectivity networks. The directed functional networks were calculated using the method of anti-symmetric delayed correlations that we developed earlier15 since this method is more sensitive to detect subtle changes in functional connectivity when compared to conventional methods. Our results show that early amyloid deposition is associated with a decrease of segregation in functional networks. These changes were also observed, although to a greater extent, in individuals that were already Aβ+ at baseline, who additionally showed changes in functional integration. Moreover, these network properties were associated with the extent of amyloid burden and preclinical cognitive composite scores. These findings suggest that, even at sub-threshold Aβ deposition levels, the decrease of directional flow in the functional network could be an indication of neuronal changes and subtle changes in cognition in individuals at the preclinical stages of AD.

## Materials & Methods

### Participants

Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. ADNI is conducted in accordance with the ethical standards of the institutional research committees and with the 1975 Helsinki declaration and its later amendments. Written informed consent, obtained from all subjects and/or authorized representatives and study partners, and ethical permits have been obtained at each participating site of ADNI and we have signed the data user agreements to analyze the data.

For the purposes of this study, only cognitively normal participants from ADNI3 were included with baseline functional MRI and at least two 18F-Florbetapir PET scans. The inclusion/exclusion criteria for ADNI are described in detail at [http://www.adni-info.org/](http://www.adni-info.org/). In short, participants were aged between 55 and 90 years, were fluent in Spanish or English while having also completed at least 6 years of education, had Clinical Dementia Rating scores of 0 and no other significant neurological disorder. We used the Preclinical Alzheimer Cognitive Composite16 (PACC, with trails test) to assess the cognitive status of the individuals. This composite calculates a composite score based on tests that assess global cognition, episodic memory and executive function and has been shown to be sensitive to the very initial signs of cognitive decline, before the appearance of clinical symptoms of mild cognitive impairment stage.

### Image Acquisition and Preprocessing

Subjects in the ADNI3 study underwent standardized MRI scanning protocols at the acquisition sites using 3T MRI scanners from different vendors, and 18F-florbetapir PET scans. The full list of MRI/PET scanners and detailed imaging protocols can be found at the ADNI study website ([https://adni.loni.usc.edu/](https://adni.loni.usc.edu/)). From the full suite of imaging data, we used the sagittal 3D accelerated MPRAGE sequence (full head coverage, voxel size = 1×1×1 mm3, field of view = 208×240×256 mm3, repetition time = 2300 ms, inversion time = 900 ms) and the axial EPI-BOLD functional MRI sequence (voxel size = 3.4×3.4×3.4 mm3, field of view = 220×220×163 mm3, repetition time = 3000 ms, echo time = 30 ms, flip angle = 90°). Functional and structural MRI scans were pre-processed using a standardized pipeline implemented in fMRIPrep17(v20.2.4, [https://fmriprep.org/en/stable/](https://fmriprep.org/en/stable/)). The resulting functional images additionally underwent motion correction using the Friston-24 head motion model18 and nuisance regression for signal from the white matter and cerebrospinal fluid. 18F-florbetapir PET scans were acquired in 4×5 minute frames, 50-70 minutes after the injection of 10 mCi dose on average.

### Group classification

We divided the participants into 3 groups based on Aβ levels measured by 18F-Florbetapir PET. Using their baseline scan as a reference, we classified the participants as being Aβ-negative or Aβ-positive using the standardized uptake value ratios (SUVRs) for a global composite region that included the caudal anterior cingulate, frontal, lateral parietal and lateral temporal gyri on 18F-Florbetapir PET, normalized by the whole cerebellum. A previously defined cut-off was used to determine amyloid-positivity19. Using the longitudinal composite-normalized cortical summary SUVR values, we further subdivided the Aβ-negative individuals into two groups that showed either positive (accumulators) annual rate of change in their Aβ levels (i.e., the change in the SUVR values per year) or remained largely stable with a small negative rate of change in Aβ levels (non-accumulators). While the negative slopes could represent measurement noise, some studies have suggested that there is a possibility that they are due to Aβ clearance14. This procedure resulted in 3 groups of participants: 31 Aβ-negative non-accumulators (Aβ−/ NAc); 46 Aβ-negative accumulators (Aβ−/ Ac) and 36 Aβ-positive (Aβ+). The characteristics of each group are summarized in Table 1, and they were compared between all groups using the Kruskal–Wallis rank sum test.

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/10/27/2022.10.26.22281539/T1)

Table 1: 
Demographic and clinical data of the participants.

### Anti-symmetric functional networks capture directed functional connectivity between brain areas

Temporal delays can arise in the interaction between brain areas because of the dispersed nature of brain regions and the limited speed of information transfer between them20. Therefore, to achieve a coherent characterization of the functional connectivity, it is crucial to capture the information contained in this complicated temporal lag structure21,22. To this purpose, we have developed an anti-symmetric correlation-based approach for determining the directed connections between pairs of brain areas, allowing for the computation of whole-brain directed functional connectivity networks15. In this approach, if one brain area’s activation time series has similar properties to the time-shifted version of the activation pattern in another brain region, then the first region is considered to have a directed interaction with the second region. The level of directed interaction is quantified by the inverse of the time lag between the time series of those regions (which captures the fact that directly connected brain regions are expected to activate with a much shorter delay that indirectly connected regions). The direction of the interaction is determined by the order of precedence in time (i.e., the early region is the source, and the late region is the end of the connection).

Figure 1A illustrates the calculation of the anti-symmetric connectivity networks for a set of five brain regions and their corresponding time series. The lagged correlation matrix can be evaluated by calculating the time-lagged Pearson’s correlation coefficient between all pairs of regions at a given temporal lag. This matrix captures the directed connection between the regions in both directions, i.e. the matrix entries *(i, j)* and *(j, i)* provide an estimate from the directed connection from region *i* to *j* and vice versa. As any other square matrix, the lagged correlation adjacency matrix can be uniquely expressed as the sum of a symmetric and anti-symmetric matrix. We use the anti-symmetric matrix to approximate the whole-brain directed functional connectivity; this method summarizes the directed connection between regions *I* and *j* with a single entry which captures its direction and the magnitude. More details about the method are presented elsewhere15.

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/10/27/2022.10.26.22281539/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2022/10/27/2022.10.26.22281539/F1)

Figure 1: Sample Differences between different groups in global and nodal directed functional network topology.
A) Overview of the calculation procedure for the anti-symmetric correlation. For simplicity, we illustrate the procedure using the time activation series for five nodes as an example. The lagged Pearson’s correlation coefficient between these time series at varying temporal lags allows the estimation of lagged correlation functional networks (in this example, at lag of 1). The lagged adjacency matrix can be written as a sum of symmetric and anti-symmetric and matrices. Here, we use the anti-symmetric matrices to estimate the functional connectivity of each individual. Differences between the different groups at lag 3 (calculated as group 2 - group 1 in the figure) in the B) clustering coefficient and C) global efficiency. The differences in the corresponding network measures between groups are plotted in orange circles as a function of network density and the upper and lower bounds of the 95% confidence intervals (CI) are plotted in blue. The differences are considered statistically significant if they fall outside the CIs. D) Differences between Aβ−/ NAc and Aβ+ groups in nodal network measures. The plotted regions remained significant after correcting for multiple comparisons using FDR at q < 0.05.

### Network construction and analysis

We calculated a 200 × 200 weighted connectivity matrix for each participant, with the edges generated using anti-symmetric correlation and the nodes corresponding to the 200 Craddock atlas brain regions23. We calculated a binary matrix for each adjacency matrix in which the correlation coefficient was assigned a value of 1 if it was greater than a certain threshold and 0 otherwise. We performed this binarization procedure throughout the complete range of network densities (*D*) available to the anti-symmetric correlation (Drange = 1% −50%) and compared the global topology of the binary networks across that range. In the case of nodal measures, we estimated measure-specific area under the curve (AUC) by numerically integrating the nodal measure values over the whole density range; the curves depict the evolution of the appropriate nodal network measure as a function of the network density for a specific brain area. These AUC values were used to assess the differences in the nodal directed connectivity patterns between the different groups. We assessed the global and nodal topology by calculating directed clustering coefficient and global efficiency using the BRAPH software package24.

### Statistical analysis

The statistical significance of differences in network measures across groups was determined using nonparametric permutation testing with 10000 permutations, with p < 0.05 considered significant for a two-tailed test of the null hypothesis. The nodal measures were corrected for multiple comparisons by using the Benjamini-Hochberg procedure25 to apply false discovery rate (FDR) corrections at q < 0.05 to adjust for the number of brain regions. All analysis were carried out using age, sex, and education as covariates. The correlation analyses were performed at each density for the global measures and for brain regions that showed between-group significant differences. All network measures were adjusted for age, sex, and education before carrying out the correlation analyses. In the case of global measures, the correlations were considered consistent if it remained significant at extended range of densities after the application of FDR correction to control for the number of densities.

## Results

### Amyloid deposition results in changes of functional segregation and integration properties of the network

We have previously shown that the changes in directed functional connectivity due to neurodegenerative processes can be captured by small temporal lags, up to the lag of 715. As the current study employs functional MRI scans that have been acquired with longer repetition times, we evaluate the between-group differences at small delays up to lag of 5, which corresponds to the same temporal scale used in ref. 15. The between-group differences in the clustering coefficient and global efficiency at lag of 3 and are shown in Figure 1B and 1C respectively, whereas the corresponding results for lags 2 and 4 are plotted in Supplementary Fig. S1. The anti-symmetric correlation methods showed widespread significant decreases in the clustering coefficient in the Aβ-negative accumulators when compared to Aβ-negative non-accumulators group. Similar differences were observed in the Aβ+ group; in addition, the Aβ+ group showed also decreased global efficiency when compared to Aβ-negative non-accumulators (Fig. 1B and 1C). The differences between Aβ+ individuals and Aβ-non-accumulators were mostly pronounced in superior frontal gyrus, caudate nucleus and anterior cingulate cortex at different temporal lags (Fig. 1D).

### Directed functional connectivity is associated with global amyloid deposition level and cognitive scores in Aβ-accumulators

In the Aβ-accumulators group, the clustering coefficient was significantly associated with baseline global SUVR values at lag 4 at high density values (33% −50%). The global efficiency showed significant associations with the SUVR values at lags 2 (5%-9% and 13% to 39%), 3 (3% to 40%) and 4 (2% to 39%). Regarding the cognitive tests, the PACC with trails test scores showed significant association with the global efficiency at lag 2 (18% to 34%). A representative correlation for each association at a single density is shown in Figure 2.

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/10/27/2022.10.26.22281539/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2022/10/27/2022.10.26.22281539/F2)

Figure 2: Correlation between Aβ deposition levels and cognitive scores and global measures for Aβ−/ Ac group.
The plots show the best line fit for Aβ−/ Ac group between baseline Aβ SUVR deposition levels and A) clustering coefficient at lag 4, and global efficiency at lags B) 2, C) 3, D)4. The correlation between PACCtrailsB test scores and global efficiency at lag 2 is shown in F). The global measure values were regressed with age, sex, and education as covariates; the residuals of the regression were used to calculate the best line fit. A representative fit at density A) 39% and B-F) 25% is shown.

## Discussion

Anti-symmetric correlations can be used for quantifying directed connectivity between brain regions by harvesting the information contained in the temporal lags between the activation time series of different regions15. In this study, we used this approach to demonstrate the impact of Aβ deposition on directed functional connectivity in a group of healthy, cognitively normal adults. We observed that groups with larger Aβ load exhibited reduced levels of functional segregation and integration in their functional connectomes, both at global network levels as well as in the superior frontal gyrus, caudate nucleus and anterior cingulate cortex. The global measures in the Aβ negative group with positive rates of amyloid accumulation were associated with global Aβ load and cognitive tests, indicating that they are sensitive to pathological and clinical alterations that may occur during preclinical AD. Overall, our results suggest that the directional flow in brain activity includes unique information that might serve as a novel biomarker to study functional abnormalities in preclinical AD.

In the preclinical stage of AD, accumulating protein aggregates already affect neurons and induce synaptic dysfunction that can be detected with fMRI even in the absence of express neurodegeneration26. In particular, before the presence of detectable amyloid plaques in the brain, soluble Aβ oligomers already appear in the intracellular space and disrupt neurotransmission on both pre- and postsynaptic levels27, while exerting a specific effect on glutamatergic transmission by interfering with the mechanisms of long-term depression and potentiation that contribute to early memory deficits during the course of the disease28. The earliest known sites of Aβ-accumulation are the precuneus, posterior cingulate and medial prefrontal cortices, areas that comprise the core of the default mode network28. Accordingly, functional connectivity measures (especially those of the default mode network) are sensitive to these early changes and were shown to correlate with pre- and postsynaptic markers in amyloid-positive individuals30. Individuals that demonstrate a trajectory of accumulating amyloid-levels still below the defined clinically relevant threshold also exhibit functional network reorganization, mainly in the default mode and salience networks31. Our results are in line with these reports and additionally show that directed approaches are more sensitive to changes due to subthreshold amyloid accumulation than conventional methods.

Anti-symmetric correlation networks had an abnormal global topology in the individuals with higher Aβ deposition, characterized by decreases in global efficiency and clustering coefficient. When compared to Aβ-non-accumulators, these differences were more pronounced in the Aβ positive group than in Aβ negative accumulators, suggesting a link between the topology and amount of Aβ in the brain. The clustering coefficient provides an estimation of the functional segregation of the connectivity network and the ability of performing specialized tasks between neighboring regions, while the global efficiency estimates the functional integration and efficiency of the information transfer between distant brain regions24, 32. The existence of locally clustered connections and high functional integration are indicative of a small-world network, an organization characteristic of a well-functioning brain network32, 33. Therefore, the reductions in the clustering coefficient and global efficiency can be interpreted as a loss of the small-world property of the functional networks, a finding consistently observed in AD8, 34, 35. Given the importance of functional connectivity for cognitive performance36, the disruptions in the integrity of the functional networks can have a significant role in the development of cognitive deficits in AD. This is also supported by our findings, which demonstrate that impaired cognitive function is linked to dysfunctional functional integration in preclinical AD.

Regarding alterations at the nodal level, we found reduced global efficiency and clustering coefficient in the superior frontal gyrus, the anterior cingulate cortex and the caudate nucleus in Aβ positive individuals. The superior frontal gyrus is part of the frontoparietal executive and control networks important in executive function37. The disruption of network measures in the superior frontal gyrus is in line with previous reports showing that executive function is affected early on in the disease course38. The anterior cingulate cortex is a prominent area of the salience network that is also impaired in AD31. Functional changes of the caudate nucleus are not widely reported in AD, however, a loss of volume in the caudate nucleus has been reported as an early sign of the disease39. Additionally, these areas participate in the function of the default mode network, one of the earliest affected brain networks in AD40. To summarize, alterations of nodal network characteristics reinforce earlier reports of executive dysfunction as one of the earliest affected cognitive domains during the course of AD, while also affecting the default mode network.

In conclusion, we show that directed functional connectivity networks are altered in sub-threshold Aβ-accumulators. The properties of these networks are associated with levels of amyloid-deposition and cognitive test scores reflecting executive function, which potentiates their use as a possible marker for early amyloid-related pathology.

## Supporting information

Supplementary Information [[supplements/281539_file02.pdf]](pending:yes)

## Data Availability

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).

## Funding

Swedish Research Council; Swedish Alzheimer Foundation; Swedish Brain Foundation; Strategic Research Area Neuroscience (StratNeuro); Center for Medical Innovation (CIMED); Foundation for Geriatric Diseases at Karolinska Institutet; Gamla Tjänarinnor; Stohne’s Foundation; Lars Hierta Memorial Foundation.

## Acknowledgements

Data collection and sharing of ADNI was funded by the National Institutes of Health Grant U01 AG024904 and Department of Defense award number W81XWH-12-2-0012. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-LaRoche Ltd and its affiliated company Genentech, Inc.; GEHealthcare; Innogenetics, N.V.; IXICO Ltd; Janssen Alzheimer Immunotherapy Research \& Development, LLC.; Johnson \& Johnson Pharmaceutical Research \& Development LLC.; Medpace, Inc.; Merck \& Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.

## Footnotes

*   Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\_to\_apply/ADNI\_Acknowledgement\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how\_to_apply/ADNI_Acknowledgement_List.pdf)

*   Received October 26, 2022.
*   Revision received October 26, 2022.
*   Accepted October 27, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  [1].Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016; 15(5):455–532.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1474-4422(16)00062-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26987701&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

2.  [2].Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers. Dement. 2016; 12(3):292–323.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jalz.2016.02.002&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27012484&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

3.  [3].Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207–16.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1474-4422(12)70291-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23332364&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000314330200021&link_type=ISI) 

4.  [4].Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353–6.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIyOTcvNTU4MC8zNTMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8xMC8yNy8yMDIyLjEwLjI2LjIyMjgxNTM5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

5.  [5].Mormino EC, Papp KV. Amyloid accumulation and cognitive decline in clinically normal older individuals: Implications for aging and early Alzheimer’s disease. J Alzheimers Dis. 2018; 64(1):S633–46.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3233/jad-179928&link_type=DOI) 

6.  [6].Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008; 65(11):1509–17.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archneur.65.11.1509&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19001171&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000260797200016&link_type=ISI) 

7.  [7].Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12(4):357–67.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1474-4422(13)70044-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23477989&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

8.  [8].Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol. 2011; 10(9):829–43.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1474-4422(11)70158-2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21778116&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000294532300011&link_type=ISI) 

9.  [9].Insel PS, Ossenkoppele R, Gessert D, et al. Time to amyloid positivity and preclinical changes in brain metabolism, atrophy, and cognition: evidence for emerging amyloid pathology in Alzheimer’s disease. Front. Neurosci. 2017; 11:281.
    
    

10. [10].Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018; 38(19):4482–9.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam5ldXJvIjtzOjU6InJlc2lkIjtzOjEwOiIzOC8xOS80NDgyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMTAvMjcvMjAyMi4xMC4yNi4yMjI4MTUzOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

11. [11].Koychev I, Vaci N, Bilgel M, et al. Prediction of rapid amyloid and phosphorylated-Tau accumulation in cognitively healthy individuals. Alzheimers Dement (DADM). 2020; 12(1):e12019.
    
    

12. [12].Mattsson N, Insel PS, Nosheny R, et al. Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014; 71(6):725–34.
    
    

13. [13].Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009; 29(40):12686–94.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam5ldXJvIjtzOjU6InJlc2lkIjtzOjExOiIyOS80MC8xMjY4NiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzEwLzI3LzIwMjIuMTAuMjYuMjIyODE1MzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

14. [14].Landau SM, Horng A, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018; 90(17):e1452–60.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0000000000005354&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29572282&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

15. [15].Mijalkov M, Volpe G, Pereira JB. Directed Brain Connectivity Identifies Widespread Functional Network Abnormalities in Parkinson’s Disease. Cereb Cortex. 2022; 32(3):593–607.
    
    

16. [16].Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014; 71(8):961–70.
    
    

17. [17].Esteban O, Markiewicz CJ, Blair RW, et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. Nat Methods. 2019; 16(1):111–6.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

18. [18].Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R. Movement-related effects in fMRI time-series. Magn Reson Med. 1996; 35(3):346–55.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mrm.1910350312&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8699946&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1996TX77500009&link_type=ISI) 

19. [19].Landau SM, Breault C, Joshi AD, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. Journal of Nuclear Medicine. 2013; 54(1):70–7.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam51bWVkIjtzOjU6InJlc2lkIjtzOjc6IjU0LzEvNzAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8xMC8yNy8yMDIyLjEwLjI2LjIyMjgxNTM5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

20. [20].Deco G, Jirsa V, McIntosh AR, Sporns O, Kötter R. Key role of coupling, delay, and noise in resting brain fluctuations. Proc Natl Acad Sci USA. 2009; 106(25):10302–7.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTA2LzI1LzEwMzAyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMTAvMjcvMjAyMi4xMC4yNi4yMjI4MTUzOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

21. [21].Lahaye, P. J., Poline, J. B., Flandin, G., Dodel, S., & Garnero, L. Functional connectivity: studying nonlinear, delayed interactions between BOLD signals. NeuroImage. 2003; 20(2):962–974.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1053-8119(03)00340-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14568466&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

22. [22].Mijalkov M, Pereira JB, Volpe G. Delayed correlations improve the reconstruction of the brain connectome. PLoS One. 2020; 15(2):e0228334.
    
    

23. [23].Craddock RC, James GA, Holtzheimer III PE, Hu XP, Mayberg HS. A whole brain fMRI atlas generated via spatially constrained spectral clustering. Hum Brain Mapp. 2012; 33(8):1914–28.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/hbm.21333&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21769991&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000306409400013&link_type=ISI) 

24. [24].Mijalkov M, Kakaei E, Pereira JB, Westman E, Volpe G, Alzheimer’s Disease Neuroimaging Initiative. BRAPH: a graph theory software for the analysis of brain connectivity. PLoS One. 2017; 12(8):e0178798.
    
    

25. [25].Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57(1):289–300.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.2517-6161.1995.tb02031.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=10592272&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

26. [26].Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7(3):280–92.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jalz.2011.03.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21514248&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000291239600005&link_type=ISI) 

27. [27].Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci Off J Soc Neurosci. 2004; 24(45):10191–200.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam5ldXJvIjtzOjU6InJlc2lkIjtzOjExOiIyNC80NS8xMDE5MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzEwLzI3LzIwMjIuMTAuMjYuMjIyODE1MzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

28. [28].Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012; 2(7):a006338.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNzaHBlcnNwZWN0bWVkIjtzOjU6InJlc2lkIjtzOjExOiIyLzcvYTAwNjMzOCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzEwLzI3LzIwMjIuMTAuMjYuMjIyODE1MzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

29. [29].Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017; 8(1):1214.
    
    

30. [30].Pereira JB, Janelidze S, Ossenkoppele R, et al. Untangling the association of amyloid β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain. 2021; 144(1):310–24.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/awaa395&link_type=DOI) 

31. [31].Butt OH, Meeker KL, Wisch JK, et al. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau. Alzheimers Dement. 2022; 18(1):116–26.
    
    

32. [32].Fornito A, Zalesky A, Breakspear M. Graph analysis of the human connectome: promise, progress, and pitfalls. Neuroimage. 2013; 80:426–44.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuroimage.2013.04.087&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23643999&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000322416000036&link_type=ISI) 

33. [33].Watts DJ, Strogatz SH. Collective dynamics of ‘small-world’networks. Nature. 1998; 393(6684):440–2.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/30918&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9623998&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000074020000035&link_type=ISI) 

34. [34].Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer’s disease. PLoS Comput Biol. 2008; 4(6):e1000100.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pcbi.1000100&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18584043&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

35. [35].Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, et al. Loss of ‘small-world’networks in Alzheimer’s disease: graph analysis of FMRI resting-state functional connectivity. PLoS One. 2010; 5(11):e13788.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0013788&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21072180&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

36. [36].Van Den Heuvel MP, Pol HE. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur Neuropsychopharmacol. 2010;20(8):519–34.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.euroneuro.2010.03.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20471808&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

37. [37].Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci. 2011; 15(10):483–506.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.tics.2011.08.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21908230&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000295662800008&link_type=ISI) 

38. [38].Tideman P, Stomrud E, Leuzy A, Mattsson-Carlgren N, Palmqvist S, Hansson O. Association of β Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology. 2022; 98(15):e1525–33
    
    

39. [39].Jiji S, Smitha KA, Gupta AK, Pillai VPM, Jayasree RS. Segmentation and volumetric analysis of the caudate nucleus in Alzheimer’s disease. Eur J Radiol. 2013; 82(9):1525–30.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ejrad.2013.03.012&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23664648&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom) 

40. [40].Jones DT, Knopman DS, Gunter JL, et al. Cascading network failure across the Alzheimer’s disease spectrum. Brain. 2016; 139(Pt 2):547–62
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/awv338&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26586695&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F27%2F2022.10.26.22281539.atom)